Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM decreased its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 65.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 475,000 shares of the company's stock after selling 889,121 shares during the quarter. Teva Pharmaceutical Industries makes up 1.2% of Monaco Asset Management SAM's portfolio, making the stock its 10th biggest position. Monaco Asset Management SAM's holdings in Teva Pharmaceutical Industries were worth $7,719,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TEVA. New Covenant Trust Company N.A. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter worth $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter worth about $30,000. Beach Investment Counsel Inc. PA bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at about $48,000. Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter valued at approximately $52,000. Finally, GAMMA Investing LLC lifted its holdings in Teva Pharmaceutical Industries by 105.7% during the 2nd quarter. GAMMA Investing LLC now owns 3,388 shares of the company's stock worth $55,000 after buying an additional 1,741 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Eric A. Hughes sold 24,537 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Eric A. Hughes sold 24,537 shares of the company's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the sale, the insider now owns 45,060 shares in the company, valued at $777,285. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Roberto Mignone sold 519,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total value of $8,838,570.00. Following the transaction, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 3rd. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Barclays lifted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, August 1st. Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, June 27th. Finally, Argus upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $18.89.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded down $0.28 on Tuesday, reaching $17.52. The company's stock had a trading volume of 7,213,430 shares, compared to its average volume of 10,042,156. Teva Pharmaceutical Industries Limited has a 52 week low of $8.06 and a 52 week high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The company has a market capitalization of $19.85 billion, a P/E ratio of -43.41, a price-to-earnings-growth ratio of 1.25 and a beta of 0.88. The firm has a fifty day moving average of $17.45 and a two-hundred day moving average of $15.81.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.35 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.